The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis on real-world chemotherapy outcomes in patients (pts) with tyrosine kinase inhibitor (TKI) resistant advanced EGFR-mutant non–small-cell lung cancer (NSCLC) in the United States.
 
Dina Oksen
Employment - Merck KGaA
 
Emmanuelle Boutmy
Employment - Merck KGaA
 
Barbara Ellers-Lenz
Employment - Merck KGaA
 
Niki Karachaliou
Employment - Merck KGaA
 
Xiuning Le
Consulting or Advisory Role - Abbvie; ArriVent Biopharma; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Hengrui Therapeutics; Janssen Oncology; Lilly; Novartis; Sensei Biotherapeutics; Spectrum Pharmaceuticals
Research Funding - ArriVent Biopharma (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Regeneron (Inst); Teligene (Inst)
Travel, Accommodations, Expenses - EMD Serono; Spectrum Pharmaceuticals